170 related articles for article (PubMed ID: 23731224)
1. Short communication: Use of raltegravir in late-presenting HIV-infected pregnant women.
Nóbrega I; Travassos AG; Haguihara T; Amorim F; Brites C
AIDS Res Hum Retroviruses; 2013 Nov; 29(11):1451-4. PubMed ID: 23731224
[TBL] [Abstract][Full Text] [Related]
2. [Factors associated with virological response in women receiving highly-active antiretroviral prophylaxis for HIV-1 mother-to-child transmission].
Palacios R; Senise JF; Vaz MJ; Castelo A
Enferm Infecc Microbiol Clin; 2008; 26(7):411-5. PubMed ID: 18842235
[TBL] [Abstract][Full Text] [Related]
3. HIV-1 viremia during the first 28 weeks of pregnancy is not associated with mother-to-child transmission.
Senise JF; Palacios R; Tanno ZN; Lunardi L; Waghabi GR; Vaz MJ; Diaz RS; Castelo A
Braz J Infect Dis; 2006 Aug; 10(4):259-63. PubMed ID: 17293908
[TBL] [Abstract][Full Text] [Related]
4. Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women.
Sturt AS; Dokubo EK; Sint TT
Cochrane Database Syst Rev; 2010 Mar; (3):CD008440. PubMed ID: 20238370
[TBL] [Abstract][Full Text] [Related]
5. HIV viraemia and mother-to-child transmission risk after antiretroviral therapy initiation in pregnancy in Cape Town, South Africa.
Myer L; Phillips TK; McIntyre JA; Hsiao NY; Petro G; Zerbe A; Ramjith J; Bekker LG; Abrams EJ
HIV Med; 2017 Feb; 18(2):80-88. PubMed ID: 27353189
[TBL] [Abstract][Full Text] [Related]
6. Raltegravir versus lopinavir/ritonavir for treatment of HIV-infected late-presenting pregnant women.
Brites C; Nóbrega I; Luz E; Travassos AG; Lorenzo C; Netto EM
HIV Clin Trials; 2018 Jun; 19(3):94-100. PubMed ID: 29629852
[TBL] [Abstract][Full Text] [Related]
7. Rapid decline in HIV viral load when introducing raltegravir-containing antiretroviral treatment late in pregnancy.
Westling K; Pettersson K; Kaldma A; Navér L
AIDS Patient Care STDS; 2012 Dec; 26(12):714-7. PubMed ID: 23101466
[TBL] [Abstract][Full Text] [Related]
8. Use of raltegravir in a late presenter HIV-1 woman in advanced gestational age: case report and literature review.
De Hoffer L; Di Biagio A; Bruzzone B; Sticchi L; Prinapori R; Gerbaldo D; Gotta C; Viscoli C
J Chemother; 2013 Jun; 25(3):181-3. PubMed ID: 23783144
[TBL] [Abstract][Full Text] [Related]
9. Maternal HIV-1 DNA load and mother-to-child transmission.
Arvold ND; Ngo-Giang-Huong N; McIntosh K; Suraseranivong V; Warachit B; Piyaworawong S; Changchit T; Lallemant M; Jourdain G;
AIDS Patient Care STDS; 2007 Sep; 21(9):638-43. PubMed ID: 17919090
[TBL] [Abstract][Full Text] [Related]
10. Impact of antiretroviral regimen on viral suppression among pregnant women living with HIV in Brazil.
Pascom ARP; Fonseca FF; Pinho RGG; Perini FB; Pereira G; Avelino-Silva VI
Int J STD AIDS; 2020 Aug; 31(9):903-910. PubMed ID: 32702281
[TBL] [Abstract][Full Text] [Related]
11. Raltegravir versus efavirenz in antiretroviral-naive pregnant women living with HIV (NICHD P1081): an open-label, randomised, controlled, phase 4 trial.
João EC; Morrison RL; Shapiro DE; Chakhtoura N; Gouvèa MIS; de Lourdes B Teixeira M; Fuller TL; Mmbaga BT; Ngocho JS; Njau BN; Violari A; Mathiba R; Essack Z; Pilotto JHS; Moreira LF; Rolon MJ; Cahn P; Prommas S; Cressey TR; Chokephaibulkit K; Werarak P; Laimon L; Hennessy R; Frenkel LM; Anthony P; Best BM; Siberry GK; Mirochnick M
Lancet HIV; 2020 May; 7(5):e322-e331. PubMed ID: 32386720
[TBL] [Abstract][Full Text] [Related]
12. Population-level risk factors for vertical transmission of HIV in the national prevention of mother-to-child transmission programme in South Africa: An ecological analysis.
Moyo F; Haeri Mazanderani A; Sherman GG; Kufa T
S Afr Med J; 2022 Mar; 112(3):219-226. PubMed ID: 35380525
[TBL] [Abstract][Full Text] [Related]
13. Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS French Perinatal Cohort.
Warszawski J; Tubiana R; Le Chenadec J; Blanche S; Teglas JP; Dollfus C; Faye A; Burgard M; Rouzioux C; Mandelbrot L;
AIDS; 2008 Jan; 22(2):289-99. PubMed ID: 18097232
[TBL] [Abstract][Full Text] [Related]
14. Raltegravir in HIV-1-Infected Pregnant Women: Pharmacokinetics, Safety, and Efficacy.
Blonk MI; Colbers AP; Hidalgo-Tenorio C; Kabeya K; Weizsäcker K; Haberl AE; Moltó J; Hawkins DA; van der Ende ME; Gingelmaier A; Taylor GP; Ivanovic J; Giaquinto C; Burger DM; ;
Clin Infect Dis; 2015 Sep; 61(5):809-16. PubMed ID: 25944344
[TBL] [Abstract][Full Text] [Related]
15. Factors associated with viral load suppression in HIV-infected pregnant women in Rio de Janeiro, Brazil.
Joao EC; Gouvêa MI; Menezes JA; Sidi LC; Cruz ML; Berardo PT; Ceci L; Cardoso CA; Teixeira Mde L; Calvet GA; Matos HJ
Int J STD AIDS; 2012 Jan; 23(1):44-7. PubMed ID: 22362687
[TBL] [Abstract][Full Text] [Related]
16. Antiretroviral treatment and prevention of peripartum and postnatal HIV transmission in West Africa: evaluation of a two-tiered approach.
Tonwe-Gold B; Ekouevi DK; Viho I; Amani-Bosse C; Toure S; Coffie PA; Rouet F; Becquet R; Leroy V; El-Sadr WM; Abrams EJ; Dabis F
PLoS Med; 2007 Aug; 4(8):e257. PubMed ID: 17713983
[TBL] [Abstract][Full Text] [Related]
17. Critical Review: Review of the Efficacy, Safety, and Pharmacokinetics of Raltegravir in Pregnancy.
Maliakkal A; Walmsley S; Tseng A
J Acquir Immune Defic Syndr; 2016 Jun; 72(2):153-61. PubMed ID: 27183177
[TBL] [Abstract][Full Text] [Related]
18. Brief Report: Vaginal Viral Shedding With Undetectable Plasma HIV Viral Load in Pregnant Women Receiving 2 Different Antiretroviral Regimens: A Randomized Clinical Trial.
Frenkel LM; Morrison RL; Fuller TL; Gouvêa MI; Benamor Teixeira ML; Coombs RW; Shapiro DE; Mirochnick M; Hennessey R; Whitson K; Chakhtoura N; João EC
J Acquir Immune Defic Syndr; 2021 Dec; 88(4):361-365. PubMed ID: 34369908
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Three Antiretroviral Regimens Initiated during Pregnancy: Clinical Experience in Rio de Janeiro.
Benamor Teixeira ML; Fuller TL; Fragoso Da Silveira Gouvêa MI; Santos Cruz ML; Ceci L; Pinheiro Lattanzi F; Sidi LC; Mendes-Silva W; Nielsen-Saines K; Joao EC
Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 33020151
[TBL] [Abstract][Full Text] [Related]
20. Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses.
Lennox JL; Dejesus E; Berger DS; Lazzarin A; Pollard RB; Ramalho Madruga JV; Zhao J; Wan H; Gilbert CL; Teppler H; Rodgers AJ; Barnard RJ; Miller MD; Dinubile MJ; Nguyen BY; Leavitt R; Sklar P;
J Acquir Immune Defic Syndr; 2010 Sep; 55(1):39-48. PubMed ID: 20404738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
